Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development and commercialization of various solutions to improve the health of insulin-requiring people with diabetes (PWD). The Company's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The Company's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The Company is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. It is also in the early stages of developing a bihormonal configuration of the iLet.
äŒæ¥ã³ãŒãBBNX
äŒç€ŸåBeta Bionics Inc
äžå Žæ¥Jan 30, 2025
æé«çµå¶è²¬ä»»è
ãCEOãSaint (Sean)
åŸæ¥å¡æ°291
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jan 30
æ¬ç€Ÿæåšå°11 Hughes
éœåžIRVINE
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·92618
é»è©±çªå·19494277785
ãŠã§ããµã€ãhttps://www.betabionics.com
äŒæ¥ã³ãŒãBBNX
äžå Žæ¥Jan 30, 2025
æé«çµå¶è²¬ä»»è
ãCEOãSaint (Sean)